EUCTR2004-001681-40-GB进行中（未招募）不适用
Comparison of inhaled ciclesonide (640 µg/day) and fluticasone propionate (1000 µg/day) in patients with moderate and severe per-sistent asthma
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 515
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-Written informed consent
- •-Male or female outpatient aged 18 to 75 years inclusive
- •-History of bronchial asthma for at least 6 months as defined by ATS criteria
- •-Good health with the exception of asthmaAsthma Treatment:
- •-Pre-treatment with CFC-beclomethasone dipropionate (CFC-BDP) > = 1000 µg/day or equivalent and a long-acting beta agonist (LABA) either in free or fixed combination. The doses of this pre-treatment has to be kept constant for at least 8 weeks directly prior to visit B0 Note: This treatment will be continued during the baseline period. All other anti-asthma medication has to be stopped at visit B0.
- •Pulmonary function:
- •-FEV1 > = 80 % of predicted measured at least 4h after the last use of short-acting beta-agonists and at least 12 h after the last use of oral and inhaled LABAs and other anti-asthma medications.
- •Asthma symptoms (based on investigator assessment and on patient’s reporting):
- •-Symptoms less than once a week, and
- •-nocturnal symptoms no more than twice a month and only
- •-occasional use of inhaled short-acting ß-agonists
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Diseases and health status:
- •-clinically relevant abnormal laboratory values suggesting an unknown disease and requiring further clinical evaluation
- •-concomitant severe diseases or diseases which are contraindications for the use of inhaled steroids (e. g. active pulmonary tuberculosis or relevant fungal, bacterial or viral infections of the lower respiratory tract demanding specific treatment), or contraindications for the use of LABAs
- •-suffering from COPD (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases causing alternating impairment in lung function
- •-current smoking with > = 10 pack-years (> = 2 pipe pack years)
- •-previous smoking with > = 10 pack-years (> = 2 pipe pack years)
- •b) Medications:
- •-use of systemic steroids during the 4 weeks (injectable depot steroids during the 6 weeks) before entry into the baseline period, or more than 3 times during the last 6 months
- •-use of other drugs not allowed
- •-washout times of drugs as defined in the study protocol cannot be adhered to
- •known or suspected hypersensitivity to inhaled steroids or to the other excipients of the MDIs
- •-intolerance to salbutamol or formoterol or to the other excipients of the devices
- •-beginning of immunotherapy within the study period (exception: Pa-tients who are undergoing immunotherapy for at least 3 months prior to B0 are eligible provided the regimen remains the same throughout the trial)
- •c) Common criteria:
- •-pregnancy
- •-intention to become pregnant during the course of the study
- •-breast feeding
- •-lack of safe contraception
- •-participation in another study within the 30 days preceding and during the present study
- •-previous enrollment into the current study
- •-known or suspected non-compliance, alcohol or drug abuse
- •-inability to follow the procedures of the study, e.g. due to language problems, psychological disorders
- •-reversal of sleep pattern (e.g. night shift workers)
研究者
相似试验
进行中（未招募）
不适用
Comparison of inhaled ciclesonide (640 g/day) and fluticasone propionate (1000 g/day) in patients with moderate and severe persistent asthma.moderate and severe persistent asthmaMedDRA version: 6.1Level: PTClassification code 10003553EUCTR2004-001681-40-ITALTANA PHARMA
进行中（未招募）
不适用
A comparative study of inhaled ciclesonide versus placebo in children with asthma (RAINBOW) - RAINBOWAsthma bronchialMedDRA version: 8.1Level: LLTClassification code 10003555Term: Asthma bronchialEUCTR2006-000803-40-DEycomed GmbH1,050
进行中（未招募）
1 期
A comparative study of inhaled ciclesonide versus placebo in children with asthma (RAINBOW)Estudio comparativo de ciclesonide inhalado frente a placebo en niños con asma - RAINBOWAsthma bronchialAsma bronquial persistenteMedDRA version: 9.0Level: LLTClassification code 10003555EUCTR2006-000803-40-ESALTANA Pharma AG1,080
进行中（未招募）
不适用
A comparative study of inhaled ciclesonide versus placebo in children with asthma (RAINBOW) - RAINBOWEUCTR2006-000803-40-HUALTANA Pharma AG1,050
进行中（未招募）
2 期
Clinical research in the treatment of the asthma crisis, at emergency room, comparing the ciclesonide bomb, in a dose of nine sprays, with hydrocortisone, corticosteroid injected into the veibronchial asthma crisispredominantly allergic asthmaJ45.0RBR-6xwc26niversidade Federal de São Paulo-Escola Paulista de Medicina